AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1724233 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (disopyramide and mexiletine)
Number of subjects: 29
Study 1724233 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide and mexiletine combination
Number of subjects: 29
Study 6963006 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 ppm fluoride dentifrice
Number of subjects: 541
Study 6963006 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ppm fluoride dentifrice
Number of subjects: 541
Study 6963006 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 541
Study 31002475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg once a day (QD) for 3 months (Group A)
Number of subjects: 100
Study 31002475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg twice a day (BID) for 3 months (Group B)
Number of subjects: 100
Study 31002475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg BID plus mosapride citrate 5 mg three times a day (TID) for 3 months (Group C)
Number of subjects: 100
Study 31002475 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 100
Study 29345213 — intervention group
Group type: EXPERIMENTAL
Intervention: Matcha green tea drinks (1 g of Matcha premium grade; OMGTea Ltd., Brighton, UK) consumed the day before and 2 hours before the walk
Number of subjects: 13
Study 26163671 — intervention group
Group type: EXPERIMENTAL
Intervention: Right neurofeedback group
Number of subjects: 60
Study 26163671 — intervention group
Group type: COMPARATOR
Intervention: Left neurofeedback group
Number of subjects: 60
Study 26163671 — intervention group
Group type: COMPARATOR
Intervention: Placebo neurofeedback group
Number of subjects: 60
Study 23820226 — intervention group
Group type: EXPERIMENTAL
Intervention: ICL (implantable collamer lenses)
Number of subjects: 24
Study 23820226 — intervention group
Group type: COMPARATOR
Intervention: Veriflex lenses (AMO)
Number of subjects: 24
Study 23820226 — intervention group
Group type: EXPERIMENTAL
Intervention: ICL
Number of subjects: 24
Study 23820226 — intervention group
Group type: COMPARATOR
Intervention: Veriflex
Number of subjects: 24
Study 21791662 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir (400 mg, 600 mg, and 900 mg twice daily) in combination with pegylated interferon α‐2a (180 μg once weekly) and ribavirin (1000‐1200 mg/day)
Number of subjects: 0
Study 21791662 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir (100 mg, 200 mg, and 300 mg 3 times daily) in combination with pegylated interferon α‐2a and ribavirin
Number of subjects: 0
Study 21791662 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with standard of care
Number of subjects: 0
Study 20028566 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy
Number of subjects: 560
Study 20028566 — intervention group
Group type: COMPARATOR
Intervention: No irradiation
Number of subjects: 560
Study 18080597 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean section (CS)
Number of subjects: 50
Study 18080597 — intervention group
Group type: COMPARATOR
Intervention: Induction of labour with misoprostol
Number of subjects: 50
Study 15030626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup critics (Australians)
Number of subjects: 3
Study 15030626 — intervention group
Group type: COMPARATOR
Intervention: Outgroup critics (foreigners)
Number of subjects: 3
Study 12529064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both personalized feedback and self-help book
Number of subjects: 86
Study 12529064 — intervention group
Group type: COMPARATOR
Intervention: Personalized feedback only
Number of subjects: 86
Study 12529064 — intervention group
Group type: COMPARATOR
Intervention: Self-help book only
Number of subjects: 86
Study 12529064 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 86
Study 9642510 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2 g/d
Number of subjects: 82
Study 9642510 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3 g/d
Number of subjects: 82
Study 9642510 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3 g/d with low cyclosporine and steroid doses
Number of subjects: 82
Study 9642510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 8033372 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (SAL, 0.08 mg/kg orally)
Number of subjects: 14
Study 8033372 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (ARG, 0.5 g/kg i.v.)
Number of subjects: 14
Study 8033372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD, 120 mg orally)
Number of subjects: 14
Study 8033372 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg i.v.)
Number of subjects: 14
Study 3180373 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy subgroup at 0.5 times defibrillation threshold
Number of subjects: 49
Study 3180373 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy subgroup at 1.0 times defibrillation threshold
Number of subjects: 49
Study 3180373 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy subgroup at 1.5 times defibrillation threshold
Number of subjects: 49
Study 3180373 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy subgroup at 2.0 times defibrillation threshold
Number of subjects: 49
Study 3180373 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy subgroup at 2.5 times defibrillation threshold
Number of subjects: 49
Study 30255228 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium bicarbonate (KHCO3) supplementation (90 mmol daily) during bed rest
Number of subjects: 7
Study 30255228 — intervention group
Group type: COMPARATOR
Intervention: Bed rest only (control)
Number of subjects: 7
Study 28751663 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate long-acting injectables (1-monthly and 3-monthly)
Number of subjects: 1498
Study 28751663 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from oral antipsychotics to long-acting injectables
Number of subjects: 1498
Study 26473104 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 171
Study 26473104 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (Intubation)
Number of subjects: 171
Study 23819342 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (68.7 ± 4.17 mg/day)
Number of subjects: 60
Study 23819342 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5.5 ± 0.34 mg/day)
Number of subjects: 60
Study 20952556 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure (specifically PM(2.5), NO, NO(2))
Number of subjects: 184
Study 20952556 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure (specifically NO and NO(2))
Number of subjects: 184
Study 20952556 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure (specifically black carbon)
Number of subjects: 184
Study 17697406 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO+leu
Number of subjects: 8
Study 17697406 — intervention group
Group type: COMPARATOR
Intervention: CHO+PRO
Number of subjects: 8
Study 17001070 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 109143
Study 12612232 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal feeding volumes (20 mL/kg/d for the first 10 days)
Number of subjects: 141
Study 12612232 — intervention group
Group type: COMPARATOR
Intervention: Advancing feeding volumes (20 mL/kg/d on day 1, increased by 20 mL/kg/d up to 140 mL/kg/d)
Number of subjects: 141
Study 12612232 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal feeding volumes
Number of subjects: 141
Study 12612232 — intervention group
Group type: COMPARATOR
Intervention: Advancing feeding volumes
Number of subjects: 141
Study 10839897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (1.5 microg/kg)
Number of subjects: 7
Study 10839897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (3.0 microg/kg)
Number of subjects: 7
Study 10839897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (1.5 and 3.0 microg/kg)
Number of subjects: 7
Study 9089424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous neu‐metoclopramide (1.8 mg/kg)
Number of subjects: 19
Study 9089424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular neu‐metoclopramide (1.8 mg/kg)
Number of subjects: 19
Study 9089424 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metoclopramide (1.8 mg/kg)
Number of subjects: 19
Study 9089424 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 19
Study 9089424 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metoclopramide
Number of subjects: 19
Study 9089424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous neu‐metoclopramide
Number of subjects: 19
Study 9089424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular neu‐metoclopramide
Number of subjects: 19
Study 8262291 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg prostaglandin E2 (PGE2), repeated daily if necessary (group 1)
Number of subjects: 84
Study 8262291 — intervention group
Group type: COMPARATOR
Intervention: 0.50 mg prostaglandin E2 (PGE2) (group 2)
Number of subjects: 84
Study 8262291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 4037023 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat
Number of subjects: 24
Study 4037023 — intervention group
Group type: COMPARATOR
Intervention: Healon
Number of subjects: 24
Study 29426286 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 35
Study 29426286 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepirudin
Number of subjects: 35
Study 29426286 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 35
Study 25887828 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident surgeons
Number of subjects: 143
Study 25887828 — intervention group
Group type: COMPARATOR
Intervention: Attending surgeons
Number of subjects: 143
Study 25518484 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinsing with 50 ml of 1% urea solution
Number of subjects: 62
Study 25518484 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinsing with various concentrations and amounts of urea solution
Number of subjects: 62
Study 23011264 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week handgrip exercise training
Number of subjects: 32
Study 23011264 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 32
Study 20388471 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuntai Capsule (6 g three times a day)
Number of subjects: 57
Study 20388471 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogen (CEE) (0.3 mg and 0.6 mg alternately once a day, average dose of 0.45 mg/d)
Number of subjects: 57
Study 20388471 — intervention group
Group type: COMPARATOR
Intervention: Control group (CEE)
Number of subjects: 57
Study 17611730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention on the primary care level
Number of subjects: 2930
Study 16117859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensite/NavX system (group I, n = 40)
Number of subjects: 75
Study 16117859 — intervention group
Group type: COMPARATOR
Intervention: CARTO system (group II, n = 35)
Number of subjects: 75
Study 11880065 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose gatifloxacin (400 mg)
Number of subjects: 100
Study 11880065 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day gatifloxacin (200 mg daily)
Number of subjects: 100
Study 11880065 — intervention group
Group type: COMPARATOR
Intervention: 3-day ciprofloxacin (100 mg twice daily)
Number of subjects: 100
Study 10075897 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous spatial priming task
Number of subjects: 0
Study 10075897 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous expectancy cueing task
Number of subjects: 0
Study 10075897 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both tasks
Number of subjects: 0
Study 7747859 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg.kg‐1
Number of subjects: 20
Study 7747859 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.75 mg.kg‐1 and atropine 0.015 mg.kg‐1
Number of subjects: 20
Study 7747859 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 20
Study 2202550 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release indomethacin tablets, 75 mg given at night
Number of subjects: 77
Study 2202550 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release indomethacin capsules, 25 mg given 3-times daily
Number of subjects: 77
Study 6115730 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg
Number of subjects: 7
Study 6115730 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg
Number of subjects: 7
Study 6115730 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 7
Study 6115730 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 7
Study 6115730 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 7
Study 6115730 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (all doses)
Number of subjects: 7
Study 6115730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31473465 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma self-foot reflexology for 6 weeks
Number of subjects: 63
Study 31473465 — intervention group
Group type: COMPARATOR
Intervention: Control group (identical aroma self-foot reflexology training provided 6 weeks later)
Number of subjects: 63
Study 28499749 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic resection (AR)
Number of subjects: 105
Study 28499749 — intervention group
Group type: COMPARATOR
Intervention: Non-anatomic resection (NAR)
Number of subjects: 105
Study 25981871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo explanation
Number of subjects: 66
Study 25981871 — intervention group
Group type: COMPARATOR
Intervention: Biological explanation
Number of subjects: 66
Study 23736793 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP) treatment (9 injections over 1 year, 2.0 to 2.5-fold platelet concentration)
Number of subjects: 50
Study 21839625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 40 μg
Number of subjects: 284
Study 21839625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 μg
Number of subjects: 284
Study 21839625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 μg
Number of subjects: 284
Study 21839625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 21839625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (pooled)
Number of subjects: 284
Study 21839625 — intervention group
Group type: COMPARATOR
Intervention: Ciclesonide and Placebo (all groups)
Number of subjects: 284
Study 21839625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 284
Study 21839625 — intervention group
Group type: COMPARATOR
Intervention: Ciclesonide and Placebo
Number of subjects: 284
Study 19177320 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of tomatoes and tomato products
Number of subjects: 0
Study 19177320 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato products
Number of subjects: 0
Study 19177320 — intervention group
Group type: COMPARATOR
Intervention: Isolated lycopene
Number of subjects: 0
Study 19177320 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene ingestion from tomato products
Number of subjects: 0
Study 17718361 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal distractors (photographs of recognizable objects)
Number of subjects: 0
Study 17718361 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimerical distractors (created by interchanging parts between normal objects)
Number of subjects: 0
Study 15101652 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher rate of 140 pps
Number of subjects: 0
Study 15101652 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing the target sentence at 140 pps
Number of subjects: 0
Study 15101652 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing the target on odd-numbered channels and the masker on even-numbered channels (or vice versa)
Number of subjects: 0
Study 15101652 — intervention group
Group type: EXPERIMENTAL
Intervention: Maskers scaled by -9 dB relative to a target sentence
Number of subjects: 0
Study 14764389 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg/Indapamide 0.625 mg (very low dose combination therapy)
Number of subjects: 0
Study 14764389 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril plus Indapamide (very low doses)
Number of subjects: 0
Study 9666549 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler examination of the urethra
Number of subjects: 67
Study 9666549 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler and linear endovaginal sonography
Number of subjects: 67
Study 7710569 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluconate (100 mg/kg)
Number of subjects: 43
Study 7710569 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 43
Study 2551520 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-adjusted 3% 2-chloroprocaine (2-CP) with 3 mEq NaHCO3
Number of subjects: 40
Study 2551520 — intervention group
Group type: COMPARATOR
Intervention: 3% 2-chloroprocaine (2-CP) with 3 ml 0.9% NaCl (Control)
Number of subjects: 40
Study 333341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucolytic and decongestive treatment
Number of subjects: 228
Study 333341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 333341 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous antibiotic treatment for acute otitis media
Number of subjects: 228
Study 31435769 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to major depressive disorder (MDD) assessed through 72 independent single-nucleotide polymorphisms as instrumental variables.
Number of subjects: 34000
Study 31435769 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to major depressive disorder (MDD)
Number of subjects: 34000
Study 28827011 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine (4-16 mg/24 h)
Number of subjects: 346
Study 28827011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study 28827011 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 346
Study 25827547 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunglasses from authorized sellers
Number of subjects: 348
Study 25827547 — intervention group
Group type: COMPARATOR
Intervention: Sunglasses from unauthorized sellers
Number of subjects: 348
Study 23433094 — intervention group
Group type: EXPERIMENTAL
Intervention: A736V TMPRSS6 polymorphism in CHD patients
Number of subjects: 199
Study 23433094 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD patients without acute inflammation and overt iron deficiency (C reactive protein <1 mg/dl and ferritin >30 ng/ml; n=86)
Number of subjects: 199
Study 23433094 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD patients without acute inflammation and severe iron deficiency
Number of subjects: 199
Study 23433094 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD patients with HFE gene mutations
Number of subjects: 199
Study 23433094 — intervention group
Group type: COMPARATOR
Intervention: CHD patients
Number of subjects: 199
Study 21110138 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet hypopharyngeal pack
Number of subjects: 0
Study 21110138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry hypopharyngeal pack
Number of subjects: 0
Study 21110138 — intervention group
Group type: COMPARATOR
Intervention: No packing (control)
Number of subjects: 0
Study 20635761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 0
Study 20635761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase with enoxaparin
Number of subjects: 0
Study 17093176 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized peanut oil (P200, P400, P800 mg I)
Number of subjects: 100
Study 17093176 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized poppy seed oil (PS400 mg I)
Number of subjects: 100
Study 17093176 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized peanut oil (P400 mg I)
Number of subjects: 100
Study 17093176 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized peanut oil and iodized poppy seed oil
Number of subjects: 100
Study 17093176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (peanut oil)
Number of subjects: 100
Study 15317642 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-release bupropion 150 mg b.i.d.
Number of subjects: 509
Study 15317642 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 509
Study 11558493 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil monotherapy
Number of subjects: 5
Study 11558493 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin-inhibitor therapy (ciclosporin or tacrolimus)
Number of subjects: 5
Study 9260125 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical pass tray
Number of subjects: 165
Study 9260125 — intervention group
Group type: COMPARATOR
Intervention: Normal instrument pass techniques (Control)
Number of subjects: 165
Study 8013271 — intervention group
Group type: EXPERIMENTAL
Intervention: Moguisteine (200 mg t.i.d. for four days)
Number of subjects: 87
Study 8013271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 8013271 — intervention group
Group type: EXPERIMENTAL
Intervention: Moguisteine
Number of subjects: 87
Study 3471525 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclarubicin, cytarabine and thioguanine (TAA)
Number of subjects: 23
Study 3471525 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin, cytarabine and thioguanine (TAD)
Number of subjects: 23
Study 30127510 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA) combined with working memory training (WMT) for 20 minutes, eight sessions
Number of subjects: 40
Study 30127510 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40